Nitroxide derivatives of non-steroidal anti-inflammatory drugs exert anti-inflammatory and superoxide dismutase scavenging properties in A459 cells

British Journal of Pharmacology

Volumn 165, Issue 4 B, 2012, Pages 1058-1067

  Flores Santana, Wilmarie ^a   Moody, Terry ^a   Chen, Weibin ^b   Gorczynski, Michael J ^b   Shoman, Mai E ^b   Velázquez, Carlos ^c   Thetford, Angela ^a   Mitchell, James B ^a   Cherukuri, Murali K ^a   King, S Bruce ^b   Wink, David A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

antioxidants; cancer; inflammation; nitrosative stress; nitroxides; NSAIDS

Indexed keywords

2,2,6,6 TETRAMETHYL 1 PIPERIDINYLOXY; 2,2,6,6 TETRAMETHYL 1 PIPERIDINYLOXY ACETYLSALICYLIC ACID; 2,2,6,6 TETRAMETHYL 1 PIPERIDINYLOXY INDOMETACIN; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CYTOCHROME C; INDOMETACIN; LEUKOTRIENE B4; NITROXIDE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN A549; CHEMICAL MODIFICATION; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ELECTRON SPIN RESONANCE; ENZYME ASSAY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL TOXICITY; IN VIVO STUDY; LUNG CARCINOMA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PAW EDEMA; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT; SINGLE DRUG DOSE; STOMACH ULCER; ULCEROGENIC INDEX;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ASPIRIN; CARRAGEENAN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIC N-OXIDES; DINOPROSTONE; DISEASE MODELS, ANIMAL; EDEMA; FEMALE; HUMANS; INDOMETHACIN; LEUKOTRIENE B4; MICE; MICE, NUDE; RATS; STOMACH ULCER; SUPEROXIDE DISMUTASE;

EID: 84863033299     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01527.x     Document Type: Article

References (43)

1. Bastos-Pereira AL, Lugarini D, de Oliveira-Christoff A, Avila TV, Teixeira S, Pires AD, et al,. (2010). Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism. Cancer Chemother Pharmacol 65: 267-276.
2. Choy H, Milas L, (2003). Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 95: 1440-1452. (Pubitemid 37279329)
3. Cotrim AP, Sowers AL, Lodde BM, Vitolo JM, Kingman A, Russo A, et al,. (2005). Kinetics of tempol for prevention of xerostomia following head and neck irradiation in a mouse model. Clin Cancer Res 11: 7564-7568. (Pubitemid 41507719)
4. Dajani EZ, Islam K, (2008). Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol 59 (Suppl. 2): 117-133.
5. DeGraff WG, Krishna MC, Russo A, Mitchell JB, (1992). Antimutagenicity of a low molecular weight superoxide dismutase mimic against oxidative mutagens. Environ Mol Mutagen 19: 21-26.
6. Del Soldato P, Sorrentino R, Pinto A, (1999). NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci 20: 319-323. (Pubitemid 29366810)
7. Dhanasekaran A, Kotamraju S, Karunakaran C, Kalivendi SV, Thomas S, Joseph J, et al,. (2005). Mitochondria superoxide dismutase mimetic inhibits peroxide-induced oxidative damage and apoptosis: role of mitochondrial superoxide. Free Radic Bio Med 39: 567-583. (Pubitemid 41112099)
8. Hahn SM, Tochner Z, Krishna CM, Glass J, Wilson L, Samuni A, et al,. (1992). Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res 52: 1750-1753.
9. Haj-Yehia A, Nassar T, (2002). Beneficial effects of tempoyl nitrate, a bifunctional SOD-mimic NO-donor, on diabetes induced endothelial dysfunction in rat. J Mol Cell Cardiol 34: A27-A27.
10. Halliwell B, (1991). Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 91: 14S-22S.
11. Jiang JF, Stoyanovsky DA, Belikova NA, Tyurina YY, Zhao Q, Tungekar MA, et al,. (2009). A mitochondria-targeted triphenylphosphonium-conjugated nitroxide functions as a radioprotector/mitigator. Radiat Res 172: 706-717.
12. Kaza CS, Kashfi K, Rigas B, (2002). Colon cancer prevention with NO-releasing NSAIDs. Prostaglandins Other Lipid Mediat 67: 107-120. (Pubitemid 34241449)
13. Krishna MC, Grahame DA, Samuni A, Mitchell JB, Russo A, (1992). Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. Proc Natl Acad Sci USA 89: 5537-5541.
14. Krishna MC, Russo A, Mitchell JB, Goldstein S, Dafni H, Samuni A, (1996). Do nitroxide antioxidants act as scavengers of O2-. or as SOD mimics? J Biol Chem 271: 26026-26031. (Pubitemid 26347441)
15. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK, (2007). Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med 42: 706-719. (Pubitemid 46205152)
16. Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, et al,. (2005). A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11: 3342-3348. (Pubitemid 40627885)
17. Liao Z, Mason KA, Milas L, (2007). Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs 67: 821-845. (Pubitemid 46607385)
18. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP, (2003). Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 62: 501-509. (Pubitemid 36606279)
19. Martínez-González J, Badimon L, (2007). Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des 13: 2215-2227. (Pubitemid 47321572)
20. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, et al,. (2008). Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 117: 2626-2636.
21. Monti E, Cova D, Guido E, Morelli R, Oliva C, (1996). Protective effect of the nitroxide tempol against the cardiotoxicity of adriamycin. Free Radic Biol Med 21: 463-470. (Pubitemid 26313942)
22. Nakao A, Sugimoto R, Billiar TR, McCurry KR, (2009). Therapeutic antioxidant medical gas. J Clin Biochem Nutr 44: 1-13.
23. National Research Council (1996). Guide for the Care and Use of Laboratory Animals (ISBN 0309053773). Institute of Laboratory Animal Research, Commission on Life Sciences. National Academy Press: Washington DC.
24. Patel K, Chen Y, Dennehy K, Blau J, Connors S, Mendonca M, et al,. (2006). Acute antihypertensive action of nitroxides in the spontaneously hypertensive rat. Am J Physiol Regul Integr Comp Physiol 290: R37-R43.
25. Rachmilewitz D, Karmeli F, Okon E, Samuni A, (1994). A novel antiulcerogenic stable radical prevents gastric mucosal lesions in rats. Gut 35: 1181-1188. (Pubitemid 24277328)
26. Rigas B, Kalofonos H, Lebovics E, Vagenakis AG, (2003). NO-NSAIDs and cancer: promising novel agents. Dig Liver Dis 35 (Suppl. 2): S27-S34. (Pubitemid 41070467)
27. Samuni A, Krishna CM, Mitchell JB, Collins CR, Russo A, (1990). Superoxide reaction with nitroxides. Free Radic Res Commun 9: 241-249. (Pubitemid 20376777)
28. Samuni A, Mitchell JB, DeGraff W, Krishna CM, Samuni U, Russo A, (1991). Nitroxide SOD-mimics: modes of action. Free Radic Res Commun 12-13 (Pt 1): 187-194.
29. Samuni AM, DeGraff W, Krishna MC, Mitchell JB, (2001). Cellular sites of H2O2-induced damage and their protection by nitroxides. Biochim Biophys Acta 1525: 70-76. (Pubitemid 32149979)
30. Samuni Y, Gamson J, Samuni A, Yamada K, Russo A, Krishna MC, et al,. (2004). Factors influencing nitroxide reduction and cytotoxicity in vitro. Antioxid Redox Signal 6: 587-595. (Pubitemid 38625378)
31. Samuni Y, Cook JA, Choudhuri R, Degraff W, Sowers AL, Krishna MC, et al,. (2010). Inhibition of adipogenesis by Tempol in 3T3-L1 cells. Free Radic Biol Med 49: 667-673.
32. Shishodia S, Koul D, Aggarwal BB, (2004). Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 173: 2011-2022. (Pubitemid 38971638)
33. Soule BP, Hyodo F, Matsumoto K, Simone NL, Cook JA, Krishna MC, et al,. (2007). The chemistry and biology of nitroxide compounds. Free Radic Biol Med 42: 1632-1650. (Pubitemid 46617154)
34. Suleyman H, Albayrak A, Bilici M, Cadirci E, Halici Z, (2010). Different mechanisms in formation and prevention of indomethacin-induced gastric ulcers. Inflammation 33: 224-234.
35. Swartz HM, Sentjurc M, Morse PD II, (1986). Cellular metabolism of water-soluble nitroxides: effect on rate of reduction of cell/nitroxide ratio, oxygen concentrations and permeability of nitroxides. Biochim Biophys Acta 888: 82-90. (Pubitemid 16031410)
36. Ulrich CM, Bigler J, Potter JD, (2006). Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6: 130-140. (Pubitemid 43361545)
37. Vane JR, (1971). Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 231: 232-235.
38. Vane JR, Bakhle YS, Botting RM, (1998). Cyclooxlygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120.
39. Velázquez C, Praveen Rao PN, Knaus EE, (2005). Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J Med Chem 48: 4061-4067. (Pubitemid 40800614)
40. Velázquez CA, Praveen Rao PN, Citro ML, Keefer LK, Knaus EE, (2007). O2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies. Bioorg Med Chem 15: 4767-4774. (Pubitemid 46836847)
41. Wasserman GF, Nix PT, Koul AK, Warme PK, (1980). Semi-synthetic analogs of cytochrome c. Substitutions for methionine at position 80. Biochim Biophys Acta 623: 457-460.
42. Winter CA, Risley EA, Nuss GW, (1962). Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med 111: 544-547.
43. Zhang QS, Eaton L, Snyder ER, Houghtaling S, Mitchell JB, Finegold M, et al,. (2008). Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice. Cancer Res 68: 1601-1608. (Pubitemid 351346870)